Segment Information

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 16 – SEGMENT INFORMATION

For the year ended December 31, 2020, the Company operated in three reportable business segments - (1) the real property operating segment, (2) the medical related consulting services segment, and (3) the performing development services for hospitals and other customers and sales of developed products to hospitals and other customers segment.

Due to the winding down of the development services and sales of developed products segment in 2020, the Company no longer has any material revenues or expenses in this segment. As a result, commencing from the first quarter of 2021, the Company’s chief operating decision maker no longer reviews development services and sales of developed products operating results.

For the year ended December 31, 2021, the Company operated in two reportable business segments - (1) the real property operating segment, and (2) the medical related consulting services segment.

The Company’s reportable segments are strategic business units that offer different services and products. They are managed separately based on the fundamental differences in their operations. Information with respect to these reportable business segments for the years ended December 31, 2021 and 2020 was as follows:

	Years Ended December 31,
	2021			2020
Revenues
Real property operations	$	1,203,560		$	1,206,854
Medical related consulting services		187,412			170,908
Total		1,390,972			1,377,762
Costs and expenses
Real property operations		829,287			851,754
Medical related consulting services		147,167			135,805
Total		976,454			987,559
Gross profit
Real property operations		374,273			355,100
Medical related consulting services		40,245			35,103
Total		414,518			390,203
Other operating expenses
Real property operations		381,266			418,863
Medical related consulting services		469,942			577,962
Development services and sales of developed products		-			123,546
Corporate/Other		8,397,140			11,723,851
Total		9,248,348			12,844,222
Other (expense) income
Interest expense
Corporate/Other		(200,477	)		(168,762	)
Total		(200,477	)		(168,762	)
Other income (expense)
Real property operations		115			(921	)
Medical related consulting services		(61,494	)		(55,964	)
Development services and sales of developed products		-			228
Corporate/Other		5,187			-
Total		(56,192	)		(56,657	)
Total other expense, net		(256,669	)		(225,419	)
Net loss
Real property operations		6,878			64,684
Medical related consulting services		491,191			598,823
Development services and sales of developed products		-			123,318
Corporate/Other		8,592,430			11,892,613
Total	$	9,090,499		$	12,679,438

Identifiable long-lived tangible assets at December 31, 2021 and 2020	December 31, 2021		December 31, 2020
Real property operations	$	7,537,281	$	7,697,473
Medical related consulting services		742		223,459
Development services and sales of developed products		-		243,869
Corporate/Other		352,294		-
Total	$	7,890,317	$	8,164,801

Identifiable long-lived tangible assets at December 31, 2021 and 2020	December 31, 2021		December 31, 2020
United States	$	7,583,880	$	7,764,947
China		306,437		399,854
Total	$	7,890,317	$	8,164,801